Effects of intensive blood pressure treatment on acute kidney injury events in the Systolic Blood Pressure Intervention Trial (SPRINT). Am J Kidney Dis. 2018;71:352 361. 151. Obi Y, Kalantar-Zadeh K, Shintani A, et al. Estimated glomerular ltration rate and the risk-bene t pro le of intensive blood pressure control amongst nondiabetic patients: a post hoc analysis of a randomized clinical trial. J Intern Med. 2018;283:314 327. 152. Nguyen LS. Effect of additional antihypertensive medications in patients with high-risk hypertension: a post hoc analysis of the SPRINT (Systolic Blood Pressure Intervention Trial) database. J Clin Hypertens (Greenwich). 2018;20:814 815. 153. Markovitz AA, Mack JA, Nallamothu BK, et al. Incremental effects of antihypertensive drugs: instrumental variable analysis. BMJ. 2017;359: j5542. 154. Bress AP, Bellows BK, King JB, et al. Cost-effectiveness of intensive versus standard blood-pressure control. N Engl J Med. 2017;377:745 755. 155. Wang MC, Tsai WC, Chen JY, et al. Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease. Am J Kidney Dis. 2005;45:494 501. 156. Zhang L, Zhao F, Yang Y, et al. Association between carotid artery intima-media thickness and early-stage CKD in a Chinese population. Am J Kidney Dis. 2007;49:786 792. 157. National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management. NICE guideline [NG136]. Available at: 2021. 158. Nerenberg KA, Zarnke KB, Leung AA, et al. Hypertension Canada s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children. Can J Cardiol. 2018;34:506 525. 159. Hiremath S, Sapir-Pichhadze R, Nakhla M, et al. Hypertension Canada s 2020 evidence review and guidelines for the management of resistant hypertension. Can J Cardiol. 2020;36:625 634. 160. Muntner P, Carey RM, Jamerson K, et al. 